View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. Technology
March 1, 2010

US Pharma Firm Chooses OmniComm’s TrialMaster For Phase III Study On CNS Disorders

OmniComm Systems, a global provider of eClinical solutions, was chosen by a pharmaceutical company to provide its EDC Solution TrialMaster for a Phase III study of a drug to test a central nervous system disorder.

By CBR Staff Writer

The contract is for in excess of $200,000 and total revenue generated from this customer exceeds $750,000 over the last six months.

Stephen Johnson, COO of OmniComm Systems, said: OmniComm continues to enhance clinical trial outcomes through TrialMaster. We are gratified that another customer has entrusted us with managing their data in a pivotal study. Our ability to attract and retain leading pharmaceutical companies has contributed to a strong start in 2010.

OmniComm Systems provides internet solutions to pharmaceutical, biotechnology, research and medical device organizations that conduct clinical trial research. OmniComm Systems has US headquarters in Fort Lauderdale, Florida and European headquarters in Bonn, Germany, with satellite offices in New Jersey and the UK. It also has offices throughout the Europe and US.

Content from our partners
Rethinking cloud: challenging assumptions, learning lessons
DTX Manchester welcomes leading tech talent from across the region and beyond
The hidden complexities of deploying AI in your business

Websites in our network
Select and enter your corporate email address Tech Monitor's research, insight and analysis examines the frontiers of digital transformation to help tech leaders navigate the future. Our Changelog newsletter delivers our best work to your inbox every week.
  • CIO
  • CTO
  • CISO
  • CSO
  • CFO
  • CDO
  • CEO
  • Architect Founder
  • MD
  • Director
  • Manager
  • Other
Visit our privacy policy for more information about our services, how Progressive Media Investments may use, process and share your personal data, including information on your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.